Current Report Filing (8-k)
January 15 2019 - 5:17PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 15, 2019
Date of Report
MARKER
THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-37939
|
45-4497941
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
5 West Forsyth Street
Suite 200
Jacksonville, FL
|
|
32202
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(904) 516-5436
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On January 15,
2019, Marker Therapeutics, Inc. (“Marker” or the “Company”) issued a press release announcing that the
Center for Cell and Gene Therapy at Baylor College of Medicine was to present data from four abstracts at the meetings of the American
Society for Blood and Marrow Transplantation (“ASBMT”)
.
The studies summarize data achieved using multi-tumor
antigen specific T cells that were developed at Baylor College of Medicine and exclusively licensed to the Company. The meetings
of ASBMT are from February 20-24, 2019 and will take place in Houston, Texas.
A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
In accordance with the requirements of the
Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this
15
th
day of January, 2019.
|
|
|
|
|
MARKER THERAPEUTICS, INC.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
BY:
|
/s/ Michael Loiacono
|
|
|
|
Michael Loiacono
|
|
|
|
Chief Accounting Officer
|
|
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024